A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts

Biomaterials

Volumn 52, Issue 1, 2015, Pages 148-160

  Liu, Jin ^a,b   Dang, Lei ^a,b   Li, Defang ^a,b   Liang, Chao ^a,b,c   He, Xiaojuan ^a,b,d   Wu, Heng ^a,b   Qian, Airong ^a,c   Yang, Zhijun ^a   Au, Doris W T ^e   Chiang, Michael W L ^e   Zhang, Bao Ting ^f   Han, Quanbin ^a   Yue, Kevin K M ^a   Zhang, Hongqi ^a   Lv, Changwei ^g   Pan, Xiaohua ^h   Xu, Jiake ⁱ   Bian, Zhaoxiang ^a   Shang, Peng ^c   Tan, Weihong ^j,k   Liang, Zicai ^a,l   Guo, Baosheng ^a,b,c   Lu, Aiping ^a,b,d   Zhang, Ge ^a,b,c   more..

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b Kunshan Industrial Technology Research Institute   (China)

^c NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

^d INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^e CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^h MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF FLORIDA   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l PEKING UNIVERSITY   (China)

more..

Author keywords

Bone resorption; MicroRNA; Osteoclast; Targeted delivery system

Indexed keywords

BONE; HYDROXYAPATITE; MAMMALS; MODULATORS;

BONE RESORPTION; CLINICAL TRANSLATION; MICRORNAS; OSTEOCLAST; TARGETED DELIVERY; TARGETED DELIVERY SYSTEMS; TARGETING DELIVERIES; TRABECULAR ARCHITECTURE;

RNA;

ANTAGOMIR; HYDROXYAPATITE; LIPOSOME; MICRORNA; MIRN148 MICRORNA, MOUSE; OLIGONUCLEOTIDE; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; BONE DISEASE; CELL SELECTION; CELLULAR DISTRIBUTION; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MICROPLATE READER; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; THERAPY EFFECT; TISSUE DISTRIBUTION; ANIMAL; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; GENE THERAPY; GENETICS; METABOLISM; MOUSE; PATHOLOGY; PROCEDURES; THERAPY;

MUS;

ANIMALS; BONE RESORPTION; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC THERAPY; LIPOSOMES; MICE; MICE, INBRED C57BL; MICRORNAS; OLIGONUCLEOTIDES; OSTEOCLASTS; PEPTIDES;

EID: 84932616935     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.007     Document Type: Article

References (34)

1. Edwards J.R. Osteoclasts: malefactors of disease and targets for treatment. Discov Med 2012, 13(70):201-210.
2. Cheng P., Chen C., He H.B., Hu R., Zhou H.D., Xie H., et al. miR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene homolog B. JBone Min Res 2013, 28(5):1180-1190.
3. Kagiya T., Nakamura S. Expression profiling of microRNAs in RAW264.7 cells treated with a combination of tumor necrosis factor alpha and RANKL during osteoclast differentiation. JPeriodontal Res 2013, 48(3):373-385.
4. Zhang J., Zhao H., Chen J., Xia B., Jin Y., Wei W., et al. Interferon-beta-induced miR-155 inhibits osteoclast differentiation by targeting SOCS1 and MITF. FEBS Lett 2012, 586(19):3255-3262.
5. Gong M., Ma J., Guillemette R., Zhou M., Yang Y., Yang Y., et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Molecular cancer research. MCR 2014, 12(1):101-110.
6. Rossi M., Pitari M.R., Amodio N., Di Martino M.T., Conforti F., Leone E., et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. JCell Physiol 2013, 228(7):1506-1515.
7. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. NEngl J Med 2013, 368(18):1685-1694.
8. Stenvang J., Petri A., Lindow M., Obad S., Kauppinen S. Inhibition of microRNA function by antimiR oligonucleotides. Silence 2012, 3(1):1.
9. Nana-Sinkam S.P., Croce C.M. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013, 93(1):98-104.
10. Hydbring P., Badalian-Very G. Clinical applications of microRNAs. F1000 Res 2013, 2:136.
11. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41(7):2971-3010.
12. Wang D., Miller S.C., Shlyakhtenko L.S., Portillo A.M., Liu X.M., Papangkorn K., et al. Osteotropic peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007, 18(5):1375-1378.
13. Wang D., Sima M., Mosley R.L., Davda J.P., Tietze N., Miller S.C., et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 2006, 3(6):717-725.
14. Wang D., Miller S., Sima M., Kopeckova P., Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003, 14(5):853-859.
15. Zhang G., Guo B., Wu H., Tang T., Zhang B.T., Zheng L., et al. Adelivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012, 18(2):307-314.
16. Jensen D.K., Jensen L.B., Koocheki S., Bengtson L., Cun D., Nielsen H.M., et al. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. Journal of controlled release. Off J Control Release Soc 2012, 157(1):141-148.
17. Gao J., Sun J., Li H., Liu W., Zhang Y., Li B., et al. Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing. Biomaterials 2010, 31(9):2655-2664.
18. Peer D., Park E.J., Morishita Y., Carman C.V., Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 2008, 319(5863):627-630.
19. Mendonca L.S., Firmino F., Moreira J.N., Pedroso de Lima M.C., Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 2010, 21(1):157-168.
20. Santos A.O., da Silva L.C., Bimbo L.M., de Lima M.C., Simoes S., Moreira J.N. Design of peptide-targeted liposomes containing nucleic acids. Biochim Biophys Acta 2010, 1798(3):433-441.
21. Cardoso A., Trabulo S., Moreira J.N., Duzgunes N., de Lima M.C. Targeted lipoplexes for siRNA delivery. Methods Enzym 2009, 465:267-287.
22. Ishikawa S., Arase N., Suenaga T., Saita Y., Noda M., Kuriyama T., et al. Involvement of FcRgamma in signal transduction of osteoclast-associated receptor (OSCAR). Int Immunol 2004, 16(7):1019-1025.
23. Kim N., Takami M., Rho J., Josien R., Choi Y. Anovel member of the leukocyte receptor complex regulates osteoclast differentiation. JExp Med 2002, 195(2):201-209.
24. Naylor K., Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012, 8(7):379-389.
25. Liu X.Y., Ruan L.M., Mao W.W., Wang J.Q., Shen Y.Q., Sui M.H. Preparation of RGD-modified long circulating liposome loading matrine, and its invitro anti-cancer effects. Int J Med Sci 2010, 7(4):197-208.
26. Harris T.J., Green J.J., Fung P.W., Langer R., Anderson D.G., Bhatia S.N. Tissue-specific gene delivery via nanoparticle coating. Biomaterials 2010, 31(5):998-1006.
27. Yokogawa K., Toshima K., Yamoto K., Nishioka T., Sakura N., Miyamoto K. Pharmacokinetic advantage of an intranasal preparation of a novel anti-osteoporosis drug, L-Asp-hexapeptide-conjugated estradiol. Biol Pharm Bull 2006, 29(6):1229-1233.
28. Wang X., Guo B., Li Q., Peng J., Yang Z., Wang A., et al. miR-214 targets ATF4 to inhibit bone formation. Nat Med 2013, 19(1):93-100.
29. Zhang G., Sheng H., He Y.X., Xie X.H., Wang Y.X., Lee K.M., et al. Continuous occurrence of both insufficient neovascularization and elevated vascular permeability in rabbit proximal femur during inadequate repair of steroid-associated osteonecrotic lesions. Arthritis Rheum 2009, 60(10):2966-2977.
30. Guo B., Zhang B., Zheng L., Tang T., Liu J., Wu H., et al. Therapeutic RNA interference targeting CKIP-1 with a cross-species sequence to stimulate bone formation. Bone 2014, 59:76-88.
31. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry Nomenclature Committee. JBone Min Res 1987, 2(6):595-610.
32. Chang T.C., Mendell J.T. microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet 2007, 8:215-239.
33. Sayed D., Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011, 91(3):827-887.
34. Li M., Marin-Muller C., Bharadwaj U., Chow K.H., Yao Q., Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J Surg 2009, 33(4):667-684.